

REMARKS

With the instant Preliminary Amendment, claims 5-17 have been amended. New claims 18-19 are added. After entry, claims 1-19 are pending and under consideration.

The claims have been amended to conform to U.S. practice without prejudice to Applicants' ability to pursue any amended subject matter in the instant application or in one or more continuation, division or continuation-in-part applications. In particular, claims 5, 12 and 17 have been amended to remove multiple dependencies. Claims 6-11 are amended to more specifically define and distinctly claim the subject matter by using the term "pharmaceutical composition" in place of "medication." Claim 12-16 are amended into a proper method of treatment format. Claims 18-19 are added.

Applicants submit that the amendments do not possess new matter because they merely change claim dependencies and format without prejudice. Applicants respectfully request their entry to the specification.

CONCLUSION

Applicants submit that claims 1-19 satisfy all of the criteria for patentability and are in condition for allowance. An early indication of the same and passage of claims 1-19 to issuance is therefore kindly solicited.

No fees in addition to the fee under 35 U.S.C. § 371 are believed due in connection with this Amendment. However, pursuant to 37 C.F.R. §1.136 (a)(3), the Commissioner is authorized to charge all required fees, fees under 37 C.F.R. §1.17 and all required extension of time fees, or credit any overpayment, to Jones Day, U.S. Deposit Account No. 503013 (Order No. 129955-999004).

Respectfully submitted,

Date: September 23, 2005



Kam W. Law

44,205

(Reg. No.)

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017-6702
(212) 326-3939